All Posts

Effective remediation during regulatory scrutiny requires cross-functional leadership and prioritization, not simply procedural compliance. Having led product teams through an FDA enforcement action, I have seen firsthand how the difference between leadership-driven remediation and compliance-driven remediation determines whether a company emerges stronger or merely survives. The Compliance Trap When a company faces a warning letter, a Form 483, or other regulatory enforcemen

Regulatory interactions often reshape medical device products more than market feedback does. Yet many companies treat regulatory engagement as an obstacle to be managed rather than a design input to be integrated. In my experience, the companies that treat regulatory feedback as a constraint — in the engineering sense of the word — build better products and reach the market with fewer surprises. The Regulatory Interaction as a Signal Every FDA interaction — whether a pre-sub

Once a strategic alternatives process begins, optionality narrows quickly. What starts as an open exploration of paths forward — partnerships, capital raises, divestitures, mergers — rapidly becomes a constrained decision environment where governance discipline matters more than at any other time. The Paradox of Strategic Alternatives The term strategic alternatives implies breadth — a deliberate assessment of all available options. In practice, the process creates its own mo

Transaction diligence in regulated medical technology environments is less about financial modeling and more about identifying where risk resides — technically, operationally, and organizationally. Yet many diligence processes remain disproportionately focused on valuation mechanics while underweighting the product, regulatory, and quality-system factors that ultimately determine whether a deal creates or destroys value. Where the Real Risk Lives In medtech transactions, the

Many medical device disputes hinge less on product failure than on how decisions were documented. Operating agreements, design controls, CAPA records, and risk assessments often become central facts in litigation — not because the product malfunctioned, but because the decision-making process was inadequately recorded or inconsistently followed. Documentation as Evidence In regulated medical technology, documentation is not just a compliance requirement — it is a contemporane

In complex medical device disputes, technical understanding often lags legal framing. Counsel may have a clear theory of the case, but if that theory is not grounded in an accurate understanding of how the device was designed, how it is used clinically, and how it is regulated, the strategy rests on an unstable foundation. The Gap Between Legal Theory and Technical Reality Medical devices are complex systems that operate at the intersection of engineering, regulatory science,

Clearly defined scope, entry, and exit points are not administrative details — they are core governance mechanisms. In my experience across advisory, board, and expert witness engagements, poorly scoped work is one of the most common sources of diluted decision quality and blurred accountability. Scope Discipline as a Governance Tool When an engagement lacks clear boundaries, several things tend to happen. Roles blur between management and advisors. Deliverables expand withou

In governance and advisory contexts, independence of judgment often matters more than raw experience — particularly when decisions involve uncertainty, regulatory risk, or long-term consequences. This is a principle I return to frequently, whether I am serving as a board director, advising on a transaction, or providing expert analysis in a litigation matter. Experience Without Independence Is Incomplete Experience is essential — there is no substitute for having been in the